Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock.

Several other analysts have also recently commented on CMPX. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Stock Performance

CMPX stock opened at $1.86 on Wednesday. The company has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.44. The stock has a market capitalization of $255.92 million, a P/E ratio of -5.03 and a beta of 0.92. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Research analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the business. Barclays PLC lifted its holdings in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Geode Capital Management LLC raised its position in Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the period. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics during the third quarter worth about $37,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Compass Therapeutics in the third quarter worth about $79,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at about $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.